**Eris Lifesciences Targets India’s Diabetes-Obesity Market**
Eris Lifesciences is strategically positioning itself to capitalize on India’s rapidly growing diabetes and obesity market. Based in Ahmedabad, the pharmaceutical company is poised to benefit from the exit of innovator Novo Nordisk from the human insulin sector, while also leveraging its insulin platform to capture a substantial share of the anti-obesity market. CEO Krishnakumar Vaidyanathan shared insights in a recent interview, stating, “We have a very successful insulin business with close to 10% market share in the country now. Any company that excels in insulin sales has also performed well with GLP-1 products.”
Novo Nordisk, a leading player in the insulin market with over 50% market share in India, is known for its successful anti-obesity medications, Ozempic and Wegovy. The weight loss drug market in India was valued at over ₹600 crore as of July 2025. Vaidyanathan emphasized that Eris’s insulin business is not just about product sales; it involves creating a comprehensive patient service and care platform. “There is active support from Eris’ side at the patient’s residence…given this insulin platform, we are very confident that we’ll be able to make a success of GLP-1 as well, because it will ride on this platform,” he explained.
Eris has developed a unique patient service model that includes training for insulin use, while Novo Nordisk also offers a service model supported by a vast network of physicians. GLP-1s, or glucagon-like peptide-1 agonists, are drugs designed to treat type-2 diabetes and obesity by mimicking the GLP-1 hormone, which helps regulate blood sugar and appetite.
The company plans to initially source Active Pharmaceutical Ingredients (APIs) from third parties but aims to eventually produce recombinant semaglutide in-house, while relying on external sources for synthetic semaglutide API. Eris launched liraglutide, a GLP-1 medication, in India last year and intends to be among the first to introduce generic semaglutide after its patent expiration in March 2026.
Key Highlights:
– Eris’s insulin platform serves as a foundation for expanding into GLP-1 and obesity medications.
– The company has launched liraglutide and is preparing for an early entry into the generic semaglutide market post-March 2026.
– Novo Nordisk’s withdrawal from insulin pens presents an opportunity for Eris to increase its market share.
– In-house production of insulin and GLP-1 is a strategic focus for Eris.
– Strong financial performance and earnings per share growth support the company’s expansion and debt reduction strategies.
Eris is not alone in this endeavor; major Indian pharmaceutical companies, including Dr. Reddy’s, Cipla, Sun Pharma, Zydus Lifesciences, and Natco, are also gearing up to launch generic semaglutide next year. Additionally, Eris has a pipeline of standalone insulin analogues and insulin-GLP-1 combination therapies currently in preclinical and clinical trials.
Earlier this year, Novo Nordisk announced it would discontinue pen-filled versions of its popular Human Mixtard insulin, although vial versions will remain available. This decision opens a significant market opportunity for domestic players to fill the gap in India’s ₹4,500 crore insulin market.
**FAQ**
**What is Eris Lifesciences’ strategy in the diabetes-obesity market?**
Eris Lifesciences aims to leverage its successful insulin platform to expand into the GLP-1 and obesity drug markets, especially following Novo Nordisk’s exit from certain segments.
